Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Weight gain · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state · people with treatment‐resistant schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ cardiovascular ‐ hypotension · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ hypotension compared with haloperidol (moderate certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension/desaturation · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ hypotension/desaturation compared with haloperidol (low certainty).
1 finding from 1 review
Service use: person able to be discharged home · acute psychosis
1 finding from 1 review
Mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) · acute psychosis
Droperidol showed no clear difference in mental state: mean score by 13 days (Scale for Quantification of… compared with haloperidol (low certainty).
1 finding from 1 review
Economic: direct costs · acute psychosis
1 finding from 1 review
Tranquillisation or asleep · acute psychosis
Droperidol showed no clear difference in tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes compared with haloperidol (high certainty).
1 finding from 1 review
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) · acute psychosis
Droperidol leads to lower global state: use of additional medication ‐ by 60 minutes after… compared with haloperidol (high certainty).
1 finding from 1 review
Global outcome: Number of additional injections ‐ 2‐4 injections · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 2‐4 injections compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Global outcome: Number of additional injections ‐ 5 or more · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 5 or more compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes adverse effects ‐ cardiovascular ‐ hypotension compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects ‐ important extrapyramidal adverse effects · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Adverse effects: specific ‐ seizure · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes adverse effects ‐ seizures compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Leaving the study early · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes leaving the study early compared with HALOPERIDOL (very low certainty).
1 finding from 1 review